Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: Relation to grades or histotypes

Clinical Neuropathology

Volumn 27, Issue 5, 2008, Pages 334-345

  Durand, A ^a   Champier, J ^a   Jouvet, A ^a,b   Labrousse, F ^c   Honnorat, J ^a,b   Guyotat, J ^b   Fevre Montange M ^a  

^a UNIVERSITÉ DE LYON   (France)

^b Centre de Pathologie   (France)

^c DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

c Myc; Edema; erb B2; Meningioma; Pathological subtype; sst2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MESSENGER RNA; MYC PROTEIN; NEUROFIBROMATOSIS TYPE 2 PROTEIN; NEUROFIBROMIN; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE ACTIVITY; GENE FUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR RECURRENCE;

EID: 52249109984     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp27334     Document Type: Article

References (43)

1. Andersson U, Guo D, Malmer B, Bergenheim AT, Brännström T, Hedman H, Hentiksson R. Epidermal growth factor receptor family (EGFR, erbB2-4) in gliomas and meningiomas. Acta Neuropathol. 2004; 108: 135-142.
2. Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T. Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol. 2004; 66: 155-166.
3. Benini E, Daidone MG, Pilotti S, Silvestri R. Immunoreactivity to MIB-1 in breast cancer: methodological assessment and comparison with other proliferation indices. Cell Prolif. 1997; 30: 107-115.
4. Buccoliero AM, Castiglione F, Degl'Innocenti DR, Gheri CF, Garbini F, Taddei A, Ammannati F, Mennonna P, Taddei GL. NF2 gene expression in sporadic meningiomas: relation to grades or histotypes real time-PCR study. Neuropathology. 2007; 27: 36-42.
5. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162: 156-159.
6. Chozik BS, Benzil DL, Stopa EG, Pezullo JC, Knuckey NW, Epstein MH, Finkelstein SD, Pinch PW. Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. J Neurooncol. 1996; 27: 117-126.
7. Colley SM, Tilbrook PA, Klinken SP. Increased transcription of the Eμ-myc transgene and mRNA stabilisation produce only a modest elevation in Myc protein. Oncogene. 1997; 14: 2735-2739.
8. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998; 76: 620-627.
9. Evans JJ, Jeun SS, Lee JH, Harwalkar JA, Shoshan Y, Cowell JK, Golubic M. Molecular alterations in the neurofibromatosis Type 2 gene and its protein rarely occurring in meningothelial meningiomas. J Neurosurg. 2001; 94: 111-117.
10. Feindt J, Mentlein R, Krisch B. Time-dependent influence of the somatostatin analogue octreotide on the proliferation of rat astrocytes and glioma cells. Brain Res. 1997; 746: 309-313.
11. Gay E, Vuillez JP, Palombi O, Brard PY, Bessou P, Passagia JG. Intraoperative and postoperative γ-detection of somatostatin receptors in bone-invasive en plaque meningiomas. Neurosurgery. 2005; 57: 107-113.
12. Hancq S, Salmon I, Brotchi J, De Witte O, Gabius HJ, Heizmann CW, Kiss R, Decaestecker C. S100AS: a marker of recurrence in WHO Grade I meningiomas. Neuropathol Appl Neurobiol. 2004; 30: 178-187.
13. Hanson CM, Buckley PG, Grigelioniene G, Piotrowski A, Hellstrom AR, Mantripragada K, Jarbo C, Mathiesen T, Dumanski JP. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macromutations on 22q and micro-mutations within the NF2 locus. BMC Genomics. 2007; 8: 1-16.
14. Herms JW, Von Loewenich FD, Behnke J, Markakis E, Kretzschmar HA. c-myc oncogene family expression in glioblastoma and survival. Surg Neurol. 1999; 51: 536-542.
15. Kim JH, Kim IS, Kwon SY, Jang BC, Suh SI, Shin DH, Jeon CH, Son EI, Kim SP. Mutational analysis of the NF2 gene in sporadic meningiomas by denaturing high-performance liquid chromatography. Int J Mol Med. 2006; 18: 27-32.
16. Kim JH, Lee SH, Cho KJ, Jang JJ, Hong SI, Lee JH. Enhanced expression of the c-myc protooncogene in human intracranial meningiomas. J Korean Med Sci. 1993; 8: 68-72.
17. Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, Patsouris E. Hormone receptors in nonmalignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology. 2003; 43: 280-290.
18. Lambrecht BN. Immunologists getting nervous: neuropeptides, dendritic cells and T cell activation. Respir Res. 2001; 2: 133-138.
19. Lamszus K. Meningioma pathology, genetics, and biology. J Neuropathol Exp Neurol. 2004; 63: 275-286.
20. Loke SL, Neckers LM, Schwab G, Jaffe ES. c-myc protein in normal tissue. Effects of fixation on its apparent subcellular distribution. Am J Pathol. 1988; 131: 29-37.
21. Louis DN, Scheithauer BW, Budka H, Von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P, Cavenee WK (eds). World Health Organization classification of tumors. Pathology and genetics of tumors of the nervous system. Lyon, France: IARC Press; 2000. p. 176-184.
22. Loussouarn D, Brunon J, Avet-Loiseau H, Campone M, Mosnier JF. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybrization study. Hum Pathol. 2006; 37: 415-421.
23. Lusis E, Gutmann DH. Meningioma: an update. Curr Opin Neurol. 2004; 17: 687-692.
24. Maes L, Kalala JP, Cornelissen M, De Ridder L. PCNA, Ki-67 and hTERT in residual benign meningiomas. In Vivo. 2006; 20: 271-275.
25. Nagashima G, Aoyagi M, Yamamoto S, Wakimoto H, Tamaki M, Yamamoto K, Fujimoto T, Hirakawa K. Involvement of disregulated cmyc but not c-sis/PDGF in atypical and anaplastic meningiomas. Clin Neurol Neurosurg. 2001; 103: 13-18.
26. Okuducu AF, Zils U, Michaelis SAM, Mawrin C, Von Deimling A. Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Heath Organization Grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. Cancer. 2006; 107: 1365-1372.
27. Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, Bowers DC, Lytle RA, Newsham IF, Gutmann DH. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol. 2001; 60: 994-1003.
28. Perry A, Louis DN, Sheithauer BW, Budka H, Von Demlig A. Meningioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). World Health Organization Classification of Tumors of the Central Nervous System. Lyon, France: IARC, Chapter 10; 2007. p. 164-172.
29. Pistolesi S, Fontanini G, Boldrini L, Camacci T, De Iseo K, Lupi G, Caniglia M, Mariani G, Boni G, Suriano S, Padolecchia R, Pingitore R, Parenti G. The role of somatostatin in vasogenic meningioma associated brain edema. Tumori. 2003; 89: 136-140.
30. Pistolesi S, Fontanini G, Camachi T, De Iseo K, Boldrini L, Lupi G, Padolecchia R, Pingitore R, Parenti G. Meningioma-associated brain edema: the role of angiogenic factors and pial blood supply. J Neurooncol. 2002; 60: 159-164.
31. Potti A, Panwalkar A, Langness E. Sholes K, Tendulkar K, Chittajalu S, Koch M. Role of her-2/neu overexpression and clinical features at presentation as predictive factors in meningiomas. Am J Clin Oncol. 2004; 27: 452-456.
32. Ragel BT, Jensen R. Molecular genetics of meningiomas. Neurosurg Focus. 2005; 19: E9.
33. Raggi CC, Maggi M, Renzi D, Calabro A, Bagnoni ML, Scaruffi P, Tonini GP, Pazzagli M, de Bernardi B, Bernini G, Serio G, Orlando C. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab. 2007; 85: 3866-3873.
34. Reubi JC, Maurer R, Lamberts SWJ. Somatostatin binding sites in human leptomeninx. Neurosci Lett. 1986; 70: 183-186.
35. Sakuda K, Kohda Y, Matsumoto T, Park C, Tohma Y, Hasegawa M, Kida S, Nitta H, Yamashima T, Yamashita J. Expression of NF2 gene product merlin in arachnoid villi and meningiomas. Nosuyo Bvori. 1996; 13: 145-148.
36. Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000; 6: 1865-1874.
37. Sestini R, Orlando C, Peri A, Tricario C, Pazzagli M, Serio M, Pagani A, Bussolati G, Ganchi S, Maggi M. Quantification of somatostatin receptor Type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res. 1996; 2: 1757-1765.
38. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res. 2006; 66: 673-681.
39. Strojnik T, Zidanik B, Kos J, Lah TT. Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery. 2001; 48: 598-605.
40. Surace EI, Lusis E, Murakami Y, Scheithauer BW, Perry A, Gutmann DH. Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. J Neuropathol Exp Neurol. 2004; 63: 1015-1027.
41. Tanaka K, Sato C, Maeda Y, Koike M, Matsutani M, Yamada K, Miyaki M. Establishment of a human malignant meningioma cell line with amplified c-myc oncogene. Cancer. 1989; 64: 2243-2249.
42. Tao Y, Wei Q, Xu Z, Bai R, Li Y, Luo C, Dong Y, Gao G, Lu Y. Holistic and network analysis of meningioma pathogenesis and malignancy. BioFactors. 2006; 28: 203-219.
43. Wellenreuther R, Kraus JA, Lenartz D, Menon AG, Schram J, Louis DN, Ramesh V, Gusella JF, Wiestler OD, Von Deimling A. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol. 1995; 146: 827-832.